Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Coupling of response biomarkers between tumour and peripheral blood in mesothelioma patients undergoing chemoimmunotherapy

ABSTRACT: Coupling of response biomarkers between tumour and peripheral blood in mesothelioma patients undergoing chemoimmunotherapy

PROVIDER: PRJNA1044408 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Coupling of response biomarkers between tumour and peripheral blood in mesothelioma patients undergoing chemoimmunotherapy

Project description:Platinum-based chemotherapy in combination with anti-PD-L1 antibodies has shown promising results in mesothelioma. However, the immunological mechanisms underlying its efficacy are not well understood and there are no predictive biomarkers of clinical outcomes to guide treatment decisions. Here, we combine time-course RNA sequencing of peripheral blood mononuclear cells with pre-treatment tumour transcriptome data from the 54-patient cohort in the single arm phase II DREAM study. The identified immunological correlates are predictive of response and provide further evidence for the additive nature of the interaction between platinum-based chemotherapy and PD-L1 antibodies. Our study highlights the complex, but predictive interactions between the tumour and immune cells in peripheral blood during the response to chemoimmunotherapy.

2024-10-31 | GSE248514 | GEO

Coupling of response biomarkers between tumour and peripheral blood in patients undergoing chemoimmunotherapy

Project description:Coupling of response biomarkers between tumour and peripheral blood in patients undergoing chemoimmunotherapy

| PRJNA1063601 | ENA

Coupling of response biomarkers between tumour and peripheral blood in patients undergoing chemoimmunotherapy

Project description:Coupling of response biomarkers between tumour and peripheral blood in patients undergoing chemoimmunotherapy

| PRJNA1060640 | ENA

Coupling of response biomarkers between tumour and peripheral blood in patients undergoing chemoimmunotherapy

Project description:Platinum-based chemotherapy in combination with anti-PD-L1 antibodies has shown promising results in mesothelioma. However, the immunological mechanisms underlying its efficacy are not well understood and there are no predictive biomarkers to guide treatment decisions. Here, we combine time-course RNA sequencing of peripheral blood mononuclear cells with pre-treatment tumour transcriptome data from the 54-patient single arm phase II DREAM study. Single cell RNA-seq and TCR-seq reveal CD8+ T effector memory (TEM) cells with stem-like properties are more abundant in peripheral blood of responders and this population expands upon treatment. These peripheral blood changes are linked to the transcriptional state of the tumour microenvironment. Combining information from both compartments, rather than individually, is most predictive of response. Our study highlights the complex, but predictive interactions between the tumour and immune cells in peripheral blood during the response to chemoimmunotherapy.

2024-10-31 | GSE252990 | GEO

Coupling of response biomarkers between tumour and peripheral blood in patients undergoing chemoimmunotherapy

Project description:Platinum-based chemotherapy in combination with anti-PD-L1 antibodies has shown promising results in mesothelioma. However, the immunological mechanisms underlying its efficacy are not well understood and there are no predictive biomarkers of clinical outcomes to guide treatment decisions. Here, we combine time-course RNA sequencing of peripheral blood mononuclear cells with pre-treatment tumour transcriptome data from the 54-patient cohort in the single arm phase II DREAM study. In peripheral blood, CD8 + T effector memory cells with stem-like properties are more abundant in responders at baseline, 3 weeks, and 6 weeks into therapy. These peripheral blood changes are linked to the transcriptional state of the tumour microenvironment. The identified immunological correlates are predictive of response and provide further evidence for the additive nature of the interaction between platinum-based chemotherapy and PD-L1 antibodies. Our study highlights the complex, but predictive interactions between the tumour and immune cells in peripheral blood during the response to chemoimmunotherapy.

2024-10-31 | GSE252432 | GEO

Coupling of response biomarkers between tumour and peripheral blood in patients undergoing chemoimmunotherapy II

Project description:Platinum-based chemotherapy in combination with anti-PD-L1 antibodies has shown promising results in mesothelioma. However, the immunological mechanisms underlying its efficacy are not well understood and there are no predictive biomarkers to guide treatment decisions. Here, we combine time-course RNA sequencing of peripheral blood mononuclear cells with pre-treatment tumour transcriptome data from the 54-patient single arm phase II DREAM study. Single cell RNA-seq and TCR-seq reveal CD8+ T effector memory (TEM) cells with stem-like properties are more abundant in peripheral blood of responders and this population expands upon treatment. These peripheral blood changes are linked to the transcriptional state of the tumour microenvironment. Combining information from both compartments, rather than individually, is most predictive of response. Our study highlights the complex, but predictive interactions between the tumour and immune cells in peripheral blood during the response to chemoimmunotherapy.

2024-10-31 | GSE253173 | GEO

Coupling of response biomarkers between tumour and peripheral blood in patients undergoing chemoimmunotherapy II

Project description:Coupling of response biomarkers between tumour and peripheral blood in patients undergoing chemoimmunotherapy II

| PRJNA1064153 | ENA

Gene expression changes between primary mesothelioma tumour cells and commercially available cell lines, compared to normal primary mesothelial cells

Project description:Malignant mesothelioma (MM) is an aggressive, fatal tumour strongly associated with asbestos exposure. There is an urgent need to improve MM patient outcomes and this requires functionally validated pre-clinical models. Mesothelioma-derived cell lines provide an essential and robust tool widely used for candidate drug evaluation. Although a number of cell lines are commercially available, a detailed comparison of these lines with freshly-derived primary tumour cells to validate their suitability as pre-clinical models is lacking. Patient-derived primary mesothelioma cell lines were established and characterised by gene expression profiling. Molecular profiling revealed a significantly different transcriptome in commercially available compared with primary cell lines. Primary mesothelioma cell lines are more representative of the tumour close to its native state and show a degree of molecular diversity, thus capturing the disease heterogeneity in a patient cohort.

2018-02-01 | E-MTAB-6351 | biostudies-arrayexpress

Project description:Coupling of response biomarkers between tumour and peripheral blood in patients undergoing chemoimmunotherapy

| PRJNA1044159 | ENA

Project description:Coupling of response biomarkers between tumour and peripheral blood in patients undergoing chemoimmunotherapy

| PRJNA1045322 | ENA